Tech Company Financing Transactions
Congruence Therapeutics Funding Round
On 3/23/2026, Congruence Therapeutics raised $39.5 million in investment from Dimension, OrbiMed and Amplitude Ventures.
Transaction Overview
Company Name
Announced On
3/23/2026
Transaction Type
Venture Equity
Amount
$39,500,000
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds to support the Phase 1/1b study of CGX-926, its lead program for MC4R-deficient genetic obesity, in healthy subjects and patients with MC4R-deficiency.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7171 Rue Frederick-Banting, 117 Montreal
Quebec, H4S 1Z9
CA
Quebec, H4S 1Z9
CA
Phone
Website
Email Address
Overview
Congruence Therapeutics is a drug discovery company that is uniquely harnessing the power of innovative fields such as protein dynamics, biophysics, machine learning and computational chemistry. Our ground-breaking discovery engine, Revenir, sees proteins in ways others have been unable to see - in their full dynamic state.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Clarissa Desjardins
Chief Scientific Officer
Sharath Hegde
Browse more venture capital transactions:
Prev: 3/23/2026: Above Security venture capital transaction
Next: 3/23/2026: Stealth BioTherapeutics venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs